5-benzo[1,3]dioxol-5-ylmethylene-2-methylsulfanyl-thiazol-4-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 5-benzo[1,3]dioxol-5-ylmethylene-2-methylsulfanyl-thiazol-4-one
• 英文别名: (5Z)-5-(1,3-benzodioxol-5-ylmethylidene)-2-methylsulfanyl-1,3-thiazol-4-one
• 化学式: C₁₂H₉NO₃S₂
• 分子量: 279.34
• InChiKey: XOBQIOWTTBOWOA-YHYXMXQVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  98.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-benzo[1,3]dioxol-5-ylmethylene-2-methylsulfanyl-thiazol-4-one 、 氰胺 在 potassium tert-butylate 作用下， 以 N-甲基吡咯烷酮 、 正己烷 为溶剂， 反应 3.0h， 以51%的产率得到5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene-cyanamide potassium
  参考文献：
  名称：

  [EN] 2-IMINO-4-(THIO) OXO-5-POLY CYCLOVINYLAZOLINES FOR USE AS P13 KINASE IHIBITORS
  [FR] 2-IMINO-4-(THIO) OXO-5-POLY CYCLOVINYLAZOLINES UTILISES COMME INHIBITEURS DE P13 KINASE

  摘要：

  本发明涉及Formula (1)中的2-亚胺-氮杂氧杂氮烯-乙烯融合苯衍生物，特别用于治疗和/或预防自身免疫疾病和/或炎症性疾病、心血管疾病、神经退行性疾病、肾脏疾病、血小板聚集、癌症、移植、移植排斥或肺损伤。

  公开号：

  WO2005011686A1
• 作为产物：
  描述：

  胡椒醛 在 哌啶 、 N,N-二异丙基乙胺 作用下， 以 乙醇 为溶剂， 反应 24.0h， 生成 5-benzo[1,3]dioxol-5-ylmethylene-2-methylsulfanyl-thiazol-4-one
  参考文献：
  名称：

  Design and synthesis of novel bis-thiazolone derivatives as micromolar CDC25 phosphatase inhibitors: Effect of dimerisation on phosphatase inhibition

  摘要：

  CDC25 phosphatases are involved in deregulated cell cycle progression and tumor development with poor prognosis. Among the most potent CDC25 inhibitors, quinonoid-based derivatives have been extensively studied. Dimerisation of heterocyclic quinones has led to IRC-083864, a bis-quinone compound with increased CDC25B inhibitory activity. Thirty-one bis-thiazolone derivatives were synthesized and assayed for CDC25 inhibitory activity. Most of the dimers displayed enhanced inhibitory activities with micromolar IC50 values lower than that observed for each thiazolone scaffold separately. Moreover, most of these compounds were selective CDC25 inhibitors. Dimer 40 showed an IC50 value of 2.9 mu M and could inhibit CDC25 activity without generating reactive oxygen species which is likely to occur with quinone-based inhibitors. Molecular docking studies suggested that the dimers could bind simultaneously to the active site and the inhibitor binding pocket. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.072

文献信息

• 2-Imino-4-(thio)oxo-5-poly cyclovinylazolines for use as p13 kinase ihibitors
  申请人：Rueckle Thomas

  公开号：US20070021447A1

  公开（公告）日：2007-01-25

  The present invention is related to 2-imino-azolinone-vinyl fused-benzene derivatives of Formula (1) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.

  本发明涉及公式（1）的2-亚氨基-咪唑酮-乙烯基融合苯衍生物，特别用于治疗和/或预防自身免疫性疾病和/或炎症性疾病、心血管疾病、神经退行性疾病、肾脏疾病、血小板聚集、癌症、移植、移植排斥或肺损伤。
• 2-IMINO-4-(THIO)OXO-5-POLYCYCLOVINYLAZOLINES FOR USE AS PI3 KINASE INHIBITORS
  申请人：Applied Research Systems ARS Holding N.V.

  公开号：EP1648452A1

  公开（公告）日：2006-04-26
• US8106214B2
  申请人：——

  公开号：US8106214B2

  公开（公告）日：2012-01-31